Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma

Ítems similars

• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  per: Jorge, Susan E., et al.
  Publicat: (2015)
• Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
  per: Tan, Xiang, et al.
  Publicat: (2017)
• Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
  per: Ding, Guanggui, et al.
  Publicat: (2019)
• Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping
  per: Paik, Paul K., et al.
  Publicat: (2015)
• MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life
  per: Drilon, Alexander
  Publicat: (2016)